Meeting
2017 Genitourinary Cancers Symposium
A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder.
Authors
Guarionex Joel DeCastro
Department of Urology, Columbia University Medical Center, New York, NY
Guarionex Joel DeCastro , Wilson Sui , Jamie S. Pak , Corinne T. Abate-Shen , Shing Mirn Lee , Christopher B. Anderson , Dara Holder , James M. McKiernan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02202772
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 313)
DOI
10.1200/JCO.2017.35.6_suppl.313
Abstract #
313
Poster Bd #
F2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.
First Author: Guarionex Joel DeCastro
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2017 Genitourinary Cancers Symposium
DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).
First Author: Matt D. Galsky
Poster
2016 Genitourinary Cancers Symposium
Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.
First Author: Yasuyoshi Miyata